JPWO2020047414A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047414A5 JPWO2020047414A5 JP2021510846A JP2021510846A JPWO2020047414A5 JP WO2020047414 A5 JPWO2020047414 A5 JP WO2020047414A5 JP 2021510846 A JP2021510846 A JP 2021510846A JP 2021510846 A JP2021510846 A JP 2021510846A JP WO2020047414 A5 JPWO2020047414 A5 JP WO2020047414A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- ripk2
- inhibitor
- immune cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725647P | 2018-08-31 | 2018-08-31 | |
| US62/725,647 | 2018-08-31 | ||
| PCT/US2019/049071 WO2020047414A1 (en) | 2018-08-31 | 2019-08-30 | Inhibition of rip kinases for treating neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535152A JP2021535152A (ja) | 2021-12-16 |
| JP2021535152A5 JP2021535152A5 (https=) | 2022-09-02 |
| JPWO2020047414A5 true JPWO2020047414A5 (https=) | 2022-09-02 |
Family
ID=69643080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510846A Pending JP2021535152A (ja) | 2018-08-31 | 2019-08-30 | 神経変性障害を処置するためのｒｉｐキナーゼの阻害法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20210322427A1 (https=) |
| EP (1) | EP3843773A4 (https=) |
| JP (1) | JP2021535152A (https=) |
| KR (1) | KR20210053303A (https=) |
| CN (1) | CN112638405A (https=) |
| AU (1) | AU2019328532A1 (https=) |
| CA (1) | CA3109364A1 (https=) |
| WO (1) | WO2020047414A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022072694A1 (en) * | 2020-10-02 | 2022-04-07 | The Trustees Of Dartmouth College | Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation |
| US20250122146A1 (en) * | 2021-09-30 | 2025-04-17 | The Scripps Research Institute | Compounds for reducing neuroinflammation |
| JP2025519164A (ja) * | 2022-05-27 | 2025-06-24 | ジンキュア・コーポレイション | 新規なペプチド及びその用途 |
| EP4616868A1 (en) * | 2022-11-09 | 2025-09-17 | Ningbo Combireg Pharmaceutical Technology Co., Ltd | Pharmaceutical composition of rip2 inhibitor in combination with immune checkpoint inhibitor and use thereof |
| CN116617224A (zh) * | 2023-05-04 | 2023-08-22 | 上海交通大学医学院附属瑞金医院 | OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用 |
| CN118304388B (zh) * | 2024-04-03 | 2025-02-11 | 南通大学 | Tak1在制备治疗周围神经损伤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130005726A1 (en) * | 2010-03-08 | 2013-01-03 | Derek Abbott | Compositions and methods for treating inflammatory disorders |
| WO2012021647A2 (en) * | 2010-08-10 | 2012-02-16 | Sanford-Burnham Medical Research Institute | Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof |
| WO2012026712A2 (ko) * | 2010-08-23 | 2012-03-01 | 주식회사 강스템홀딩스 | Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 |
| MX340536B (es) * | 2011-07-06 | 2016-07-13 | Sykehuset Sorlandet Hf | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). |
| WO2014066894A1 (en) * | 2012-10-26 | 2014-05-01 | Case Western Reserve University | Biomarkers for nod2 and/or rip2 activity related application |
| EP3092496B1 (en) * | 2014-01-11 | 2020-05-06 | The J. David Gladstone Institutes | In vitro assays for inhibition of microglial activation |
| US10336707B2 (en) * | 2014-12-16 | 2019-07-02 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| KR20160129609A (ko) * | 2015-04-30 | 2016-11-09 | 삼성전자주식회사 | Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도 |
-
2019
- 2019-08-30 WO PCT/US2019/049071 patent/WO2020047414A1/en not_active Ceased
- 2019-08-30 CA CA3109364A patent/CA3109364A1/en active Pending
- 2019-08-30 AU AU2019328532A patent/AU2019328532A1/en not_active Abandoned
- 2019-08-30 EP EP19853529.6A patent/EP3843773A4/en not_active Withdrawn
- 2019-08-30 KR KR1020217008526A patent/KR20210053303A/ko not_active Ceased
- 2019-08-30 JP JP2021510846A patent/JP2021535152A/ja active Pending
- 2019-08-30 CN CN201980057467.0A patent/CN112638405A/zh active Pending
- 2019-08-30 US US17/271,966 patent/US20210322427A1/en not_active Abandoned
-
2024
- 2024-06-12 US US18/741,408 patent/US20240398824A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535152A5 (https=) | ||
| Nguyen et al. | Nanotechnology-based drug delivery for central nervous system disorders | |
| JP2014517050A5 (https=) | ||
| JP2026035701A5 (https=) | ||
| JPWO1993011765A1 (ja) | （＋）アポビンカミン酸２−ニトロキシエチルエステルの新規な用途 | |
| JPWO2020047414A5 (https=) | ||
| JP2021522291A5 (https=) | ||
| JP2011504474A5 (https=) | ||
| Ivgy-May et al. | Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial | |
| JP2022508609A5 (https=) | ||
| WO2013002365A1 (ja) | 止痒剤 | |
| US20210008039A1 (en) | Promoting sleep using at1 receptor blockers | |
| Ortega et al. | Indications of dexmedetomidine in the current sedoanalgesia trends in the critical patient | |
| US6855735B2 (en) | Ketamine treatment of restless legs syndrome | |
| TWI841027B (zh) | 手部溼疹之治療 | |
| JP2019530711A5 (https=) | ||
| JP2013536206A5 (https=) | ||
| Minami et al. | Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study | |
| Pathak et al. | Recent update on barbiturate in relation to brain disorder | |
| Röhm et al. | Physostigmine for the prevention of postanaesthetic shivering following general anaesthesia–a placebo-controlled comparison with nefopam | |
| JP2017513845A5 (https=) | ||
| JPWO2021211489A5 (https=) | ||
| JPWO2019211081A5 (https=) | ||
| JP7337081B2 (ja) | レストレスレッグズ症候群を治療するための治療薬 | |
| CN111135304A (zh) | 治疗慢性、顽固性或原发性失眠症的联合用药物及其应用 |